Eton Pharmaceuticals Secures Patent for Hydrocortisone Formulation
Company Announcements

Eton Pharmaceuticals Secures Patent for Hydrocortisone Formulation

Eton Pharmaceuticals Inc (ETON) has released an update.

Eton Pharmaceuticals, Inc. has announced the grant of a U.S. patent for its ET-400 oral liquid hydrocortisone formulation, with protection until 2043. This significant development is poised for inclusion in the FDA’s Orange Book following product approval, bolstering the company’s intellectual property portfolio as they await the decision on additional related patents.

For further insights into ETON stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEton Pharmaceuticals reports Q3 EPS 2c, consensus (1c)
Catie PowersETON Earnings this Week: How Will it Perform?
TheFlyEton Pharmaceuticals awarded second patent for ET-400
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App